Open Access<p>The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma</p>
Author(s) -
Catherine Lai,
Adrese Michael Kandahari,
Chaitra S. Ujjani
Publication year - 2019
Publication title -
blood and lymphatic cancer
Language(s) - English
Resource type - Journals
ISSN - 1179-9889
DOI - 10.2147/blctt.s231821
Subject(s) - brentuximab vedotin , medicine , antibody drug conjugate , oncology , autologous stem cell transplantation , lymphoma , classical hodgkin lymphoma , cd30 , chemotherapy , hodgkin lymphoma , immunotherapy , refractory (planetary science) , antibody , immunology , monoclonal antibody , cancer , biology , astrobiology
The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.